ArticleOncotarget2018
A phase I pilot study evaluating the beneficial effects of black raspberries in patients with Barrett's esophagus.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Biomarkers of Berry Intake: Systematic Review Update.Journal of agricultural and food chemistry · 2023Pooled it
- Green Cancer Prevention and Beyond.Cancer prevention research (Philadelphia, Pa.) · 2024Review
- Berries vs. Disease: Revenge of the Phytochemicals.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Berry Extracts and Their Bioactive Compounds Mitigate LPS and DNFB-Mediated Dendritic Cell Activation and Induction of Antigen Specific T-Cell Effector Responses.Antioxidants (Basel, Switzerland) · 2023Article
- Inducible TgfbR1 and Pten deletion in a model of tongue carcinogenesis and chemoprevention.Cancer gene therapy · 2023Article
- Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota.Molecular nutrition & food research · 2022Review
- Chemopreventive Properties of Black Raspberries and Strawberries in Esophageal Cancer Review.Antioxidants (Basel, Switzerland) · 2022Review
- Black raspberry extract inhibits regulatory T-cell activity in a murine model of head and neck squamous cell carcinoma chemoprevention.Frontiers in immunology · 2022Article
- Editorial: Regulatory T lymphocytes in cancer immunity.Frontiers in immunology · 2022Article
- Familial adenomatous polyposis and changes in the gut microbiota: New insights into colorectal cancer carcinogenesis.World journal of gastrointestinal oncology · 2021Review
- Food intake biomarkers for berries and grapes.Genes & nutrition · 2020Review
- Chemopreventive Effect of Dietary Anthocyanins against Gastrointestinal Cancers: A Review of Recent Advances and Perspectives.International journal of molecular sciences · 2020Review
- Potential of the ellagic acid-derived gut microbiota metabolite - Urolithin A in gastrointestinal protection.World journal of gastroenterology · 2020Review
- The role of nutrition in influencing mechanisms involved in environmentally mediated diseases.Reviews on environmental health · 2018Review
- Exosomal formulation of anthocyanidins against multiple cancer types.Cancer letters · 2017Article
- Black raspberries in cancer clinical trials: Past, present and future.Journal of berry researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Black raspberries inhibit a broad range of cancers in preclinical models which has led to clinical evaluations targeting premalignant lesions of the colon, oral cavity and esophagus. A phase I pilot study was conducted in twenty Barrett's esophagus (BE) patients to investigate the effect of lyophilized black raspberries (LBR) on urinary metabolites and markers of lipid peroxidation, DNA damage and tissue markers of cellular proliferation, detoxification, and inflammation. Surveys, biopsies, blood and urine samples were collected before and after 6 months of LBR treatment (32 or 45 g). LBR significantly reduced urinary excretion of 8-epi-prostaglandin F2α, a marker of lipid peroxidation linked to oxidative stress and free radical damage. Urinary levels of the ellagitannin metabolites, urolithin A-glucuronide, urolithin A-sulfate and dimethylellagic acid glucuronide were significantly increased following 12 and 26 weeks of LBR consumption and may prove useful as indicators of compliance in future clinical studies. Immunohistochemical staining of BE biopsies following LBR treatment showed significant increases in mean GST-pi levels, with 55.6% of subjects responding favorably. In summary, LBR significantly decreased urinary lipid peroxidation levels and significantly increased GST-pi, a marker of detoxification, in BE epithelium. Still, LBR may need to be formulated differently, administered at higher concentrations or multiple times a day to increase efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.